Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Bruton tyrosine kinase (BTK) inhibitor is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL). Zanubrutinib, a highly selective BTK inhibitor, is approved for patients with MCL who have received ≥1 prior therapy. We report the long-term safety and efficacy results from...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yuqin, Zhou, Keshu, Zou, Dehui, Zhou, Jianfeng, Hu, Jianda, Yang, Haiyan, Zhang, Huilai, Ji, Jie, Xu, Wei, Jin, Jie, Lv, Fangfang, Feng, Ru, Gao, Sujun, Guo, Haiyi, Zhou, Lei, Huang, Jane, Novotny, William, Kim, Pil, Yu, Yiling, Wu, Binghao, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136878/
https://www.ncbi.nlm.nih.gov/pubmed/35303070
http://dx.doi.org/10.1182/blood.2021014162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136878/
https://www.ncbi.nlm.nih.gov/pubmed/35303070
http://dx.doi.org/10.1182/blood.2021014162

Ejemplares similares